Merck Wave Analysis – 8 April 2025- Merck broke strong support level 81.30
- Likely to fall to support level 75.00
Merck is under bearish pressure after breaking the strong support level 81.30 (the former monthly low from February, which stopped the earlier impulse wave 1).
The breakout of the support level 81.30 should accelerate
Key facts today
On April 15, 2025, a class action lawsuit was filed against Merck & Co. (MRK) for misleading investors about $11 billion Gardasil revenue projections, causing a 9% stock drop.
1.20 USD
15.20 B USD
56.82 B USD
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
ISIN
ARDEUT110277
FIGI
BBG000FT0R36
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Merck & Co. (NYSE: $MRK) Sets Up Q125 Earnings Call for April 24Merck & Co. (NYSE: NYSE:MRK ) will hold its Q1 2025 earnings call on April 24 at 9:00 a.m. ET. Company executives will present financial results and performance updates during the call.
As of April 4th, 2025, MRK closed at $81.47, down $4.92 (5.70%). The stock has declined steadily since peaking at
Undervalued, Oversold, Overlooked: MRK Hits The Key Zone!Hi all,
Merck & Co. (MRK) is a global pharmaceutical titan and is currently trading near its 52-week low of ~$79. Anchored by Keytruda’s 7% YoY revenue growth, a stable ~4% dividend yield, and an average fair value estimate of $156.59 (98% upside), MRK appears significantly undervalued.
Analysts f
How and When to switch from Selling Short to Buying Long Often times when the market is in a panic selling mode or trending down in a correction, stocks fall below their fundamental values. When that happens traders need to quickly close their sell short positions with buy to cover orders and prepare to start swing trading the velocity or momentum runs th
MRK 5M Long Investment Aggressive CounterTrend TradeAggressive CounterTrend Trade
- short impulse
+ exhaustion volume
+ volumed T1
+ volumed 2Sp-
+ weak test
+ first bullish bar closed entry
Calculated affordable stop limit
1/2 1M take profit
Hourly CounterTrend
"- short impulse
+ 1D SOS level"
Daily Trend
"+ long impulse
+ SOS level
- before 1/2
MRK to $98My trading plan is very simple.
I buy or sell when price tags the top or bottom of parallel channels.
I confirm when price hits Fibonacci levels.
So...
Here's why I'm picking this symbol to do the thing.
Price in channel zones at bottom of channels (period 100 52 & 26)
Stochastic Momentum Ind
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
7.33%
Maturity date
Jun 24, 2050
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
7.20%
Maturity date
Dec 10, 2061
US58933YBF1
MERCK & CO. 21/51Yield to maturity
7.14%
Maturity date
Dec 10, 2051
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042Yield to maturity
6.77%
Maturity date
Sep 15, 2042
US58933YBA2
MERCK & CO. 20/40Yield to maturity
6.56%
Maturity date
Jun 24, 2040
US58933YAT2
MERCK CO. 2045Yield to maturity
6.43%
Maturity date
Feb 10, 2045
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049Yield to maturity
6.32%
Maturity date
Mar 7, 2049
US58933YAJ4
MERCK CO. 13/43Yield to maturity
6.18%
Maturity date
May 18, 2043
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
6.00%
Maturity date
May 17, 2053
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
5.98%
Maturity date
May 17, 2063
US58933YAV7
MERCK & CO. 19/39Yield to maturity
5.88%
Maturity date
Mar 7, 2039
See all MRKD bonds
Curated watchlists where MRKD is featured.